| Hyperlipidemia is the main cause of coronary heart disease and heart cerebrovascular disease.Probiotics can effectively prevent and treat related diseases,A key concern is low viability of probiotics in end products owing to adverse conditions during the transportation,storage,marketing and consumption of product,this may mean that they no longer provide the expected health benefits.Studies have shown that microencapsulation techniques often been used to increase the viability of probiotics in adverse conditions.However,reported about the survival rate of bacteria and it's positive effect in vivo are few.We compared the quantities of LIP-1 cells in the colon luminal content obtained from rats fed with free and microencapsulated LIP-1 cells,and evaluate their cholesterol-lowering effect.In this study,microencapsulated LIP-1 or LIP-1 free cells were used to fed hyperlipidemia rats for 28 days,hyperlipidemia rats was regard as a model,then quantifying their colon colonization count of LIP-1,and evaluting their Cholesterol-lowering effect.Moreover,the possible mechanisms by which LIP-1 might exert positive effects on hypolipidaemic symptoms in vivo were also explored.1.Results from real-time quantitative PCR(qPCR)targeting to LIP-1 cells showed a higher colon colonization count of LIP-1 in the rats receiving microencapsulated than free cells(P<0.05),our results suggest that microencapsulation can be a valid strategy to improve the gut delivery and colonization of probiotics cells.2.Compared to the model group,serum levels of TC,TG and LDL levels were significantly lower while HDL were significantly higher with the groups supplemented with either microencapsulated LIP-1 or LIP-1 free cells,and microencapsulated LIP-1 was superior to LIP-1 free cells in reducing cholesterol(P<0.05),our results suggest that microencapsulation techniques help LIP-1 exert a more obvious lipid lowering effect.3.The mechanisms behind the hypolipidemic effect exerted by LIP-1 are possibly due to:(1)Compared to the model group,feces levels of CHO and TG were significantly higher with the group with microencapsulated LIP-1(P<0.05),results suggest that LIP-1 can removed cholesterol by binding it to cellular surfacesthe excretion of cholesterol.(2)Compared to the model group,serum levels of SOD and GSH-Px were significantly higher while MDA were significantly lower with the group with microencapsulated LIP-1(P<0.05),results suggest that LIP-1 could regulate lipid metabolism while removing the oxygen free radicals and increasing the antioxidant ability.(3)Compared to the model group,the relative abundances of Bilophila and Akkermansia muciniphila increased with the group with microencapsulated LIP-1(P<0.05),results suggest that LIP-1 can significantly reduce the levels of gut-derived LPS and repair the destructive intestinal mucosa,and decrease the inflammatory and related metabolic diseases.(4)Compared to the model group,the relative abundances of Bacteroides,Eubacterium,Clostridium,and Lactobacillus increased with the group with microencapsulated LIP-1(P<0.05),results suggest that LIP-1 promotes the growth of bacteria that possess bile salt hydrolase activity,they deconjugate bile salts in the gut,and enhance bile acid excretion.(5)Compared to the model group,the relative abundances of Lactobacillus,Alloprevotella,Eubacterium,Coprococcus,and Ruminococcus increased with the group with microencapsulated LIP-1(P<0.05),results suggest that SCFAs help repair any intestinal mucosal damages,inhibit the synthesis and assimilation of lipid,and hence lower the serum lipids in hyperlipidemic rats.Results show that microencapsulation can offer the protective effect for probiotics in vivo and enhances the colonization of LIP-1 in colon,thus lead to a more obvious lipid lowering effect.LIP-1 hypolipidemic mechanism is through the synergy of a variety of ways. |
PDF Full Text Request